Interim Chief Executive Officer and Chief Operating Officer
Mr. Roberts brings deep operational and financial experience to CGI with a strong track record of disciplined growth, operational excellence and shareholder value creation in multiple public and private healthcare technology and service companies including InfoLogix, AdvantEdge Healthcare Solutions, Clarient and, most recently, VirMedica. His professional background includes a deep understanding of clinical and healthcare billing, diagnostics, clinical operations, and healthcare-focused IT. In addition Mr. Roberts is a long-standing board member and incoming President-elect of the Drug Information Association (DIA), a neutral, global nonprofit association focused on advancing health care product development around the world by connecting stakeholders to interdisciplinary insights and innovation.
Mr. Roberts has a Master of Business Administration and Bachelor of Science from the University of Maine. He has served as a recognized thought leader and expert panelist for numerous publications and programs related to corporate finance and mergers and acquisitions in the healthcare industry.
Chief Accounting Officer
Igor Gitelman joined Cancer Genetics, Inc. in 2017 as principal accounting officer (Chief Accounting Officer). Prior to joining the Company, Mr. Gitelman served as an AVP of Finance and Tax at clinical diagnostic laboratory, BioReference Laboratories, Inc., from October 2005 to October 2016. During this time, Mr. Gitelman held various positions of increasing responsibility managing the company’s internal audit function, SEC financial reporting, tax and corporate finance functions as well as leading the finance team through numerous mergers and acquisitions while managing the organic growth that BioReference experienced in this time-period. Prior to that role, Mr. Gitelman was a senior manager of tax and financial reporting at Gucci Group from May 2003 to May 2005 where he managed all aspects of the company’s tax planning, compliance and audits on federal, state and international levels as well as the company’s tax accounting function. Mr. Gitelman worked as a senior intermediate accountant at UBS Painewebber from May 2000 to April 2003, and, prior to that position, Mr. Gitelman worked as an associate at PricewaterhouseCoopers, LLP from May 1998 to July 1999 serving as a consultant on various clients from July 1999 to May 2000. Mr. Gitelman holds a BBA and an MBA degree in accounting form Pace University’s Lubin School of Business. Mr. Gitelman is a Certified Public Accountant.
CHIEF MEDICAL OFFICER AND GROUP MEDICAL DIRECTOR
Dr. Rita Shaknovich brings over 10 years of experience in Hematopathology, translational research and experimental therapeutics. The focus of her research has been in epigenetic mechanisms governing normal B cell development and lymphomagenesis. Her PhD work and her postdoctoral training focused on pathobiology of hematologic malignancies. Her laboratory in Weill Cornell Medical College (WCMC) studied epigenetic mechanisms of gene regulation during normal B cell development and epigenetic changes that contribute to neoplastic transformation. Her research was funded by such agencies as NIH, STARR Cancer Consortium, Leukemia and Lymphoma Foundation (LLF) and Lymphoma Research Foundation (LRF). Her lab used genome-wide approaches to profile genome, transcriptome and methylome of B cells at different stages of development and of different subtypes of Lymphomas in order to identify novel epigenetic mechanisms of neoplastic transformation. Dr. Shaknovich has published multiple peer reviewed publications, invited reviews, and invited book chapters, as well as conducted global lectures and presentations on lymphomas.
Dr. Shaknovich received her MD and PhD degrees from the Medical Scientist training program in Mount Sinai School of Medicine in New York, after which she completed clinical training in Anatomic Pathology specializing in Hematopathology and finished her post-doctoral training in the laboratory of Dr. Ari Melnick in Weill Cornell Medical College.
Vice President, Clinical Market Development
Mr. Ash serves as Vice President, Clinical Market Development for Cancer Genetics. His primary responsibilities are overseeing sales, training, pipeline development, as well as market strategy and revenue creation in the clinical sector. Prior to joining Cancer Genetics, Mr. Ash held several executive level marketing and sales positions of increasing prominence from Vice President of Sales, Molecular for GoPath Laboratories to Director of Strategic Accounts for Response Genetics. While at Response Genetics, as a Regional Sales Director, Mr. Ash led a team of experienced, molecular oncology diagnostic sales professionals and delivered unprecedented growth for the company. As a result, Mr. Ash was promoted to Director of Strategic Accounts, where he worked on developing and converting the largest, most influential accounts in the country. In addition, Mr. Ash has co-developed core value propositions, marketing and sales differentiator strategies for not only solid tumor but also hematology testing, as well as formal presentations to venture capitalists in an effort to deliver a strong exit value to the investors. Prior to moving to the diagnostic sector, Mr. Ash worked for Eisai Oncology (pharmaceutical oncology), where he launched Halavan for late stage metastatic breast cancer as well as marketing Dacogen for myelodysplastic syndrome.
Mr. Ash has worked exclusively in the healthcare sector since 1999 and graduated from Ball State University with magna cum laude honors in both Marketing and Finance with an additional year of Pre-Medicine.
Vice President of Operations
Dr. Marella joined Cancer Genetics in April 2010. His research interests were in investigating the three dimensional structural and functional architecture of the human nucleus in normal and cancer cell types. While involved in Corporate Business Development, Dr. Marella led CGI’s Clinical Trial initiative (SELECT ONE) along with members from the research and clinical lab departments. Since June 2015, he is leading the operations of CGI’s Rutherford, New Jersey facility in addition to continuing managing several business development projects of strategic importance to the growth and expansion of CGI.
Vice President of Biopharma Solutions
Rob Fannon brings more than 10 years of experience in operations, client management, molecular test and panel development, and biorepository management to CGI. Before joining CGI, Mr. Fannon served with Roche Molecular’s Biospecimen Management Division, where he oversaw biospecimen acquisition, panel production, project management, and client relations. Prior to his tenure at Roche, Fannon served as clinical operations manager at BioServe Biotechnologies, Ltd. In Beltsville, MD, where he was responsible for sales, business development, and client relations. From 2006 to 2010, Fannon served as an editor and analyst at Stansberry and Associates Investment Research, where he established an investment advisory publication focused on investment opportunities in publicly-traded biotech, life science, and healthcare companies. Fannon also spent two years as a business development associate at the Johns Hopkins Bloomberg School of Public Health, where he assessed intellectual property opportunities and sought licensing opportunities for research with provisional patent coverage.
Mr. Fannon received his B.S. from East Carolina University and holds a Master of Public Health (MPH), and a Master of Business Administration (MBA) from Johns Hopkins University in Baltimore, MD.
Vice President, Biopharma Collaborations & Companion Diagnostics
Kamala K. Maddali, DVM, Ph.D, is Vice President, Biopharma Collaborations and Companion Diagnostics at Cancer Genetics Inc. She joined CGI in 2015, and plays a pivotal role in the biomarker and companion diagnostics strategy in the context of pharma novel drug development programs.
Dr. Maddali brings over 10 years of extensive experience of global P&L scientific and commercial management of clinical biomarker and companion diagnostics (CDx) services covering personalized medicine strategy. She has promoted the proper utilization of biomarkers, personalized medicine and diagnostics in drug development and patient management to bridge the gap between drug and diagnostic industries. She was Global Director Scientific Development -Biomarkers & Companion Diagnostics for Q2 Solutions (A Quintiles & Quest Diagnostics joint venture). She brings a lot of strategic values from her previous roles at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics.
Dr. Maddali holds a DVM Ph.D., in Pharmacology from University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India.
Dr. Maddali is CGI’s Innovation Hero as recognized by Healthcare Heroes Finalist award by NJBIZ. She initiated an actively on-going “Biopharma Collaboration” campaign where she has implemented strategic initiatives to foster positive growth of the company through the provision of high-quality, innovative, responsive services. Her goal is to ensure that every patient’s voice is heard by helping patients and pharma partners implement the right test for the right patient, thus improving the global community health by innovating the right drug.
Director of Clinical Affairs & Site Operations, CGI West
Dr. Ehab (Bob) Elkhouly is a uniquely qualified professional in the healthcare industry with proven medical, business development and operational skills. Dr. Elkhouly’s specific areas of expertise include pathology, lab medicine and molecular diagnostics with an emphasis on Oncology. As a Research Scientist at the prestigious University of Southern California-Norris Comprehensive Cancer Center, he participated in colorectal and breast cancer studies, and also collaborated in grant budgeting. He was previously recruited by Response Genetics, Inc., and quickly promoted to Director of Operations. In this capacity, he coordinated business and scientific strategies, also instituting strong outreach and awareness programs to enhance marketing initiatives through effective advocacy and education. He met numerous challenges during his administrative training at USC-Keck Medical Center and Norris Comprehensive Cancer Center, improving fiscal protocols for clinical trials and enhancing overall operational effectiveness. Most recently, he coached a team through the 2015 Business Plan Competition at the University of California, Irvine, the Paul Merage School of Business. The team included faculty members, scientists and business leaders who developed a safe proprietary cell delivery system to improve blood glucose control and alleviate diabetes complications. The team was awarded First Place Prize and received considerable monetary rewards.
A third-generation M.D., Dr. Elkhouly graduated from Cairo University School of Medicine in his native Egypt, completed three years of pathology and lab medicine residency at the USC-Keck Hospital and LAC+USC Medical Center, later earned a Health Care MBA from UC, Irvine, the Paul Merage School of Business. He will soon receive his Six Sigma Lean Green Belt Program Certification. He is currently earning a Master of Science in Clinical, Biomedical and Translational Investigations from University of Southern California – Keck School of Medicine.
Dr. Singh-Kahlon brings more than 30 years of experience in clinical cytogenetics to CGI since joining in 2010. He has over 20 years of experience in Director positions, including the last seven years in cancer, at leading commercial cytogenetics laboratories, LabCorp and Genzyme, and earlier at the University of California School of Medicine in San Francisco. Dr. Singh-Kahlon is an active member of the American College of Medical Genetics (ACMG), American Society of Human Genetics (ASHG) and the Association of Molecular Pathology (AMP). Since being at CGI, Dr. Singh-Kahlon is focused on delivering high quality diagnostic reports while maintaining industry leading turnaround times. He is involved in the expansion of CGI’s FISH test menu by introducing new testing such as the cIg-FISH used in the diagnosis of multiple myeloma, and further FISH testing validation for molecular markers such as HER2 and in Gliomas used in clinical management of solid tumors.
Director, Molecular Diagnostics
Dr. Chen ncame to CGI in 2005. Her scientific focus has been on the identification and characterization of genomic alterations in B-cell lymphoma and their prognostic implications using modern molecular techniques, including microarrays. While at MSK, she was trained in the Molecular Diagnostic Laboratory at the New York Presbyterian Hospital and Memorial Sloan-Kettering Cancer Center. Dr. Chen is certified as a High-complexity Clinical Laboratory Director (HCLD) from American Board of Bioanalysis (ABB), and a certificate of qualification as a laboratory director from the New York State Department of Health. She is an active member of the Association of Molecular Pathology. At CGI, Dr. Chen supervised the establishment of the molecular diagnostic laboratory as well as validated and acquired licensure for clinical assays at CGI with New York State and Clinical Laboratory Improvement Amendment (CLIA). She oversaw the setting up of an automated system in CGI’s molecular diagnostic lab. Now she manages the operation of the molecular lab, reviews and reports test results, as well as directing the development and validation of new clinical tests.